“The chances of surviving and recovering from acute promyelocytic leukemia, known as ‘fulminant leukemia’, previously less than 20%, today are close to 95% thanks to a targeted therapy, not chemotherapy, based on arsenic trioxide combined with acid all-trans-retinoic, a derivative of vitamin A “.
This was stated by Sergio Amadori, national president of AIL (Italian Association against leukemia – lymphomas and myeloma), on the occasion of the scientific conference ‘The challenge to complex blood cancers: from therapies without chemo to immunotherapy with Car-T. The studies of the present and the hopes of the future ‘, which was held today in virtual mode, anticipating the themes of Leukemia 2021, the biennial meeting dedicated to leukemia and beyond, whose works this year will take place on 26 and 27 April online. And on the occasion of the 10th National Conference on leukemia, sponsored by Sie (Italian Society of Hematology), Gitmo (Italian Group for Bone Marrow Transplant, Hemopoietic Stem Cells and Cell Therapy), and Gimema Foundation (Italian Group for Hematological Diseases of adult).
“In this edition of Leukemia – added Amadori – we want to give ample and scientifically correct information that highlights the progress made in all blood cancers in recent years”. And during the tenth edition of the hematology meeting, the most important scientific innovations of recent years will be discussed: chemo-free treatments, targeted therapies, oral drugs and drug combinations that are increasingly effective, better tolerated and that ensure greater survival.